NFKB1 and gastritis: Since NF-κB is also found to be chronically active in many other inflammatory diseases such as inflammatory bowel disease, arthritis, and gastritis [5], therapeutics strategies have been focused on attenuating NF-κB activity and the production of Proinflammatory cytokines, which turns out to be ineffective [6].